Reminyl Related Published Studies
Well-designed clinical trials related to Reminyl (Galantamine)
Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). [2008.10.31]
Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). [2008.09]
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. [2008.08]
Analyses of mortality risk in patients with dementia treated with galantamine. [2008.06.01]
Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). [2008.02.28]
Economic and Clinical Benefits of Galantamine in the Treatment of Mild to Moderate Alzheimer's Disease in a Korean Population: A 52-Week Prospective Study. [2008.02]
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. [2008.02]
Galantamine for the treatment of cognitive impairments in people with schizophrenia. [2008.01]
Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. [2008.01]
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. [2008]
Galantamine treatment of vascular dementia: a randomized trial. [2007.07.31]
Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. [2007.04.03]
Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial. [2007.03]
A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. [2007.03]
Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. [2006.12]
Galantamine improves cognition in schizophrenic patients stabilized on risperidone. [2006.09.15]
Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. [2006.04.11]
A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. [2006.04]
Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. [2006.03]
Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. [2006.01]
Effects of galantamine versus donepezil on sleep in patients with mild to moderate Alzheimer disease and their caregivers: a double-blind, head-to-head, randomized pilot study. [2005.10]
Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment: a double-blind placebo-controlled study. [2005.09]
Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. [2005.06]
Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. [2005]
Effects of galantamine in patients with mild Alzheimer's disease. [2004.11]
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting. [2004.11]
Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. [2004.11]
A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. [2004.10]
Effect of galantamine hydrobromide in chronic fatigue syndrome: a randomized controlled trial. [2004.09.08]
Long-term outcomes of galantamine treatment in patients with Alzheimer disease. [2004.09]
Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. [2004.07]
The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease. [2004.05]
Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. [2004.03]
The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. [2004.02]
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. [2004.01]
Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. [2004]
Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease. [2003.11]
The effects of galantamine treatment on caregiver time in Alzheimer's disease. [2003.10]
Sleep-related outcomes in persons with mild to moderate Alzheimer disease in a placebo-controlled trial of galantamine. [2003.08.01]
Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. [2003.06]
An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. [2003.06]
The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. [2003.04]
Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease. [2003]
A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. [2003]
Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. [2003]
Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis. [2003]
Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. [2002.12]
Galantamine pharmacokinetics, safety, and tolerability profiles are similar in healthy Caucasian and Japanese subjects. [2002.09]
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. [2002.04.13]
Galantamine for Alzheimer's disease. [2002]
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. [2001.11]
Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. [2001.09]
Galantamine for Alzheimer's disease. [2001]
Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. [2000.12.09]
Galantamine: additional benefits to patients with Alzheimer's disease. [2000.09]
A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. [2000.06.27]
Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. [2000.06.27]
Well-designed clinical trials possibly related to Reminyl (Galantamine)
Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. [2008.10]
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. [2008.09]
Decreased initiation of usual activities in people with mild-to-moderate Alzheimer's disease: a descriptive analysis from the VISTA clinical trial. [2008.04.11]
Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. [2008.02]
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. [2008.02]
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. [2008.02]
Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. [2007.11.27]
Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. [2007.10.09]
Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. [2007.09]
Magnetic resonance imaging predictors of cognition in mild cognitive impairment. [2007.07]
Add-on therapy with acetylcholinesterase inhibitors for memory dysfunction in schizophrenia: a systematic quantitative review, part 2. [2007.07]
Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors. [2007.04]
Cholinesterase inhibitors in dementia with Lewy bodies-a comparative analysis. [2007.01.30]
Alpha-lipoic acid as a new treatment option for Alzheimer's disease--a 48 months follow-up analysis. [2007]
Cholinesterase inhibitors for Alzheimer's disease. [2006.01.25]
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. [2005.07]
Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients. [2005.01]
Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence. [2001.09.01]
Sleep and the cholinergic rem sleep induction test in patients with primary alcoholism. [1998]
Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep. [1994.03]
Cholinergic neurotransmission, REM sleep and depression. [1994]
Other research related to Reminyl (Galantamine)
A Double Blind Comparison of Galantamine Hydrobromide ER and Placebo in Parkinson's Disease. [2008.10.17]
The safety and tolerability of galantamine in patients with epilepsy and memory difficulties. [2008.08]
Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia. [2008.08]
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. [2008.07]
The safety and tolerability of galantamine in patients with epilepsy and memory difficulties. [2008.06.13]
Lack of beneficial galantamine effect for smoking behavior: A double-blind randomized trial in people with schizophrenia. [2008.06.10]
A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. [2008.06]
The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study. [2008.06]
The clinical significance of plasmatic amyloid A{beta}-40 peptide levels in Alzheimer's disease patients treated with galantamine. [2008.06]
Safety and efficacy of galantamine in subjects with mild cognitive impairment. [2008.05.27]
Safety and efficacy of galantamine in subjects with mild cognitive impairment. [2008.03.05]
High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. [2008.03.04]
Prolonged QT interval, syncope, and delirium with galantamine. [2008.02]
Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy. [2008.02]
First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy. [2008.01]
Galantamine in Alzheimer's disease. [2008.01]
One-week dose titration of extended release galantamine in patients with Alzheimer's disease. [2008.01]
Effects of Galantamine on Measures of Attention: Results From 2 Clinical Trials in Alzheimer Disease Patients With Comparisons to Donepezil. [2008]
Galantamine in frontotemporal dementia and primary progressive aphasia. [2008]
A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. [2007.12.03]
An update on the pharmacology of galantamine. [2007.12]
Synergistic effect of combined treatment with risperidone and galantamine on phencyclidine-induced impairment of latent visuospatial learning and memory: Role of nAChR activation-dependent increase of dopamine D1 receptor-mediated neurotransmission. [2007.09]
Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. [2007.08]
|
